Sanofi Expands Rare Disease Portfolio with Blueprint Deal – Merger Arbitrage Mondays
Blueprint Medicines Corporation (BPMC): $127.85
Market Cap: $8.26 B
Deal Value: $9.1 B
France-based big pharma company Sanofi (SNY) entered a merger agreement on June 2, 2025, to acquire U.S.-based Blueprint Medicines in a deal valued at $9.1 billion, aiming to strengthen its position in rare immunology diseases.
Blueprint Medicines is a drug company that c…
Keep reading with a 7-day free trial
Subscribe to The Special Situation Report to keep reading this post and get 7 days of free access to the full post archives.